O. G. Makedonskaya
Research Subjects
O. G. Makedonskaya has a total of 25 co-authors. Here are the top co-authors by number of shared publications:
- Dmitriy S. Tikhomirov
National Medical Research Center for Hematology of the Ministry of Health of Russia
2 shared publications - R. R. Abakarov
National Research Center for Hematology
2 shared publications - Tatiana A. Tupoleva
National Medical Research Center for Hematology of the Ministry of Health of Russia
2 shared publications - Tatiana Vladimirovna Gaponova
National Medical Research Center for Hematology
2 shared publications - A. A. Gulyaeva
National Medical Research Center for Hematology
1 shared publication - E. N. Ignatova
St. Petersburg State Marine Technical University
1 shared publication
Latest Publications
- Open Access
- 18 July 2023
- Published by National Medical Research Center of Hematology of the Ministry of Health of the Russian Federation in Russian journal of hematology and transfusiology
- Vol. 68 (2) , 202-218
Comparative study of the quality of screening of donated blood for the presence of molecular markers of viral infections
Introduction. Transfusions of donor blood components are indispensable in providing medical care for a large number of conditions and diseases. Therefore, the issue of improving the quality and safety of transfusions is relevant for healthcare worldwide.Aim — to assess the quality of donor blood screening for HIV, HBV and HCV by PCR in several Russian blood banks.Methods: PCR, CLIA and ELISA.Results. A study was conducted to assess the quality of molecular screening of donated blood in medical organizations, which was carried out in two stages. Two different kits of control samples for each project stage were created and delivered to the project participants (blood banks). Each kit contained samples with or without HBV DNA / HIV RNA / HCV RNA. The first stage’s kit contained 40 samples, the second one — 10 samples. Thus, project participants performed 13 series of test runs (520 tests) on the first stage and 8 series of runs (80 tests) on the second one. The number kits copies sent to one participant was determined by the participant’s laboratory equipment. Participants who used the Cobas performed 330 tests, of which 255 were incorrect. Participants using the Procleix performed 40 tests, and 29 tests gave a false result. 140 samples were tested by AmpliSens, and results in 86 cases were incorrect. One participant used Vector-Best test kits and performed 40 tests, 16 of which returned incorrect. In total, 355 samples containing HBV DNA, 121 samples containing HCV RNA, and 82 samples containing HIV RNA were provided to project participants. HBV DNA was detected in 191 (53.8 %) of 355 samples, HCV RNA was detected in 119 (98.3 %) of 121 samples, and HIV RNA was detected in 76 (92.7 %) of 82 samples.Conclusion. The proportion of inconsistencies in the results increased depending on the decrease in the concentration of the marker being determined. Participants demonstrated the best performance results if they were using branded equipment. Such participants received the least inconsistencies. The biggest issue concerned HBV DNA detection due to a lower viremia of this pathogen. All samples with low HBV DNA levels contained anti-HBc, which indicates potential latent HBV. Therefore, it is appropriate to include anti-HBc in the routine screening of donated blood.
- 18 July 2023
- Published by National Medical Research Center of Hematology of the Ministry of Health of the Russian Federation in Russian journal of hematology and transfusiology
- Vol. 68 (2) , 202-218
Open AccessComparative study of the quality of screening of donated blood for the presence of molecular markers of viral infections
Introduction. Transfusions of donor blood components are indispensable in providing medical care for a large number of conditions and diseases. Therefore, the issue of improving the quality and safety of transfusions is relevant for healthcare worldwide.Aim — to assess the quality of donor blood screening for HIV, HBV and HCV by PCR in several Russian blood banks.Methods: PCR, CLIA and ELISA.Results. A study was conducted to assess the quality of molecular screening of donated blood in medical organizations, which was carried out in two stages. Two different kits of control samples for each project stage were created and delivered to the project participants (blood banks). Each kit contained samples with or without HBV DNA / HIV RNA / HCV RNA. The first stage’s kit contained 40 samples, the second one — 10 samples. Thus, project participants performed 13 series of test runs (520 tests) on the first stage and 8 series of runs (80 tests) on the second one. The number kits copies sent to one participant was determined by the participant’s laboratory equipment. Participants who used the Cobas performed 330 tests, of which 255 were incorrect. Participants using the Procleix performed 40 tests, and 29 tests gave a false result. 140 samples were tested by AmpliSens, and results in 86 cases were incorrect. One participant used Vector-Best test kits and performed 40 tests, 16 of which returned incorrect. In total, 355 samples containing HBV DNA, 121 samples containing HCV RNA, and 82 samples containing HIV RNA were provided to project participants. HBV DNA was detected in 191 (53.8 %) of 355 samples, HCV RNA was detected in 119 (98.3 %) of 121 samples, and HIV RNA was detected in 76 (92.7 %) of 82 samples.Conclusion. The proportion of inconsistencies in the results increased depending on the decrease in the concentration of the marker being determined. Participants demonstrated the best performance results if they were using branded equipment. Such participants received the least inconsistencies. The biggest issue concerned HBV DNA detection due to a lower viremia of this pathogen. All samples with low HBV DNA levels contained anti-HBc, which indicates potential latent HBV. Therefore, it is appropriate to include anti-HBc in the routine screening of donated blood.
- Open Access
- 2 September 2021
- Published by National Medical Research Center of Hematology of the Ministry of Health of the Russian Federation in Russian journal of hematology and transfusiology
- Vol. 66 (2) , 242-252-252
The frequency of detection of anti-HBc in blood donors from four regions of Russia
Introduction. Occult hepatitis B virus (HBV) revelation in HBV nuclear antigen testing is of particular importance to prevent transfusion infection.Aim — the identification of factors affecting the anti-HBc detection rate in donated transfusable blood components from different regions of Russia.Materials and methods. A cohort screening single-stage epidemiological study was conducted with 2,000 donor blood samples, 500 samples per each of four regions of the country, the Republics of Crimea (Simferopol) and Sakha (Yakutia), the cities of Saransk and Orenburg. Data on 968 blood samples from the National Research Center for Hematology’s donor bank were used as reference. The testing targeted HBV nuclear antigen antibodies. Positive donated blood samples were additionally tested for IgM and virus surface antigen antibodies using Abbott and Vector-Best commercial reagent kits.Results. Donor demographic profiles differed insignificantly across members of the Russian Federation. Males predominated among the donors (69.6 %). Anti-HBc was detected in 219 of 2,000 samples examined (10.9 %). The donor blood sample anti-HBc detection rate ranged from 6.0 to 21.6 %, depending on the region. Anti-HBc-positive proportions in Orenburg, Crimea, Mordovia and Sakha comprised 8.2, 8.0, 6.0 and 21.6 %, respectively (p < 0.01). First-time donors had anti-HBc in 8.06, regular donors — in 11.29 % cases. The anti-HBc detection rate varied with donor’s age, being zero or near 1 % in 20-yo or younger people. Acute HBV antibodies had zero rate in Orenburg at zero or low-titre (< 100 mIU/mL) protective antibodies; 31 total samples, 15 low-titre and 16 negative for protective antibodies. In Simferopol, acute phase antibodies were negative in 7 blood samples containing high-titre protective antibodies (> 100 mIU/mL) and in 5.0 % samples with their low or zero levels. In Yakutian donors, acute phase antibodies were revealed only at protective antibodies negative. In Saransk, this marker was equal-proportion at zero and high-titre protective antibodies (3.3 % each).Conclusion. Transfusion component procurement from younger donors should be prioritised as enhancing haemotransfusion viral safety. Positive occult HBV tests were less common in regions with low HBV incidence.
- 2 September 2021
- Published by National Medical Research Center of Hematology of the Ministry of Health of the Russian Federation in Russian journal of hematology and transfusiology
- Vol. 66 (2) , 242-252-252
Open AccessThe frequency of detection of anti-HBc in blood donors from four regions of Russia
Introduction. Occult hepatitis B virus (HBV) revelation in HBV nuclear antigen testing is of particular importance to prevent transfusion infection.Aim — the identification of factors affecting the anti-HBc detection rate in donated transfusable blood components from different regions of Russia.Materials and methods. A cohort screening single-stage epidemiological study was conducted with 2,000 donor blood samples, 500 samples per each of four regions of the country, the Republics of Crimea (Simferopol) and Sakha (Yakutia), the cities of Saransk and Orenburg. Data on 968 blood samples from the National Research Center for Hematology’s donor bank were used as reference. The testing targeted HBV nuclear antigen antibodies. Positive donated blood samples were additionally tested for IgM and virus surface antigen antibodies using Abbott and Vector-Best commercial reagent kits.Results. Donor demographic profiles differed insignificantly across members of the Russian Federation. Males predominated among the donors (69.6 %). Anti-HBc was detected in 219 of 2,000 samples examined (10.9 %). The donor blood sample anti-HBc detection rate ranged from 6.0 to 21.6 %, depending on the region. Anti-HBc-positive proportions in Orenburg, Crimea, Mordovia and Sakha comprised 8.2, 8.0, 6.0 and 21.6 %, respectively (p < 0.01). First-time donors had anti-HBc in 8.06, regular donors — in 11.29 % cases. The anti-HBc detection rate varied with donor’s age, being zero or near 1 % in 20-yo or younger people. Acute HBV antibodies had zero rate in Orenburg at zero or low-titre (< 100 mIU/mL) protective antibodies; 31 total samples, 15 low-titre and 16 negative for protective antibodies. In Simferopol, acute phase antibodies were negative in 7 blood samples containing high-titre protective antibodies (> 100 mIU/mL) and in 5.0 % samples with their low or zero levels. In Yakutian donors, acute phase antibodies were revealed only at protective antibodies negative. In Saransk, this marker was equal-proportion at zero and high-titre protective antibodies (3.3 % each).Conclusion. Transfusion component procurement from younger donors should be prioritised as enhancing haemotransfusion viral safety. Positive occult HBV tests were less common in regions with low HBV incidence.